Combined peritoneal and liver metastases in colorectal cancer: A Dutch nationwide population-based analysis of incidence, treatment and survival

IF 3.5 2区医学 Q2 ONCOLOGY

Ejso Pub Date : 2025-03-25 DOI:10.1016/j.ejso.2025.109999

Eline H.E. van Gansewinkel , Teun B.M. van den Heuvel , Felice N. van Erning , Ignace H.J.T. De Hingh , Stefan A.W. Bouwense , Geert A. Simkens

{"title":"Combined peritoneal and liver metastases in colorectal cancer: A Dutch nationwide population-based analysis of incidence, treatment and survival","authors":"Eline H.E. van Gansewinkel , Teun B.M. van den Heuvel , Felice N. van Erning , Ignace H.J.T. De Hingh , Stefan A.W. Bouwense , Geert A. Simkens","doi":"10.1016/j.ejso.2025.109999","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>The aim of this study was to determine the incidence, treatment patterns, survival and factors associated with curative treatment in colorectal cancer patients with combined liver and peritoneal metastases using Dutch population-based data.</div></div><div><h3>Materials and methods</h3><div>Data from the Netherlands Cancer Registry were used. All patients diagnosed with synchronous isolated peritoneal and liver metastasized colorectal adenocarcinoma between January 1, 2015 and December 31, 2021 were included. Multivariable regression analyses were performed to identify factors associated with receiving curative treatment. Survival rates were calculated for patients undergoing palliative and curative treatment separately.</div></div><div><h3>Results</h3><div>Of 14627 patients with colorectal adenocarcinoma in the study period, 927 patients (6.3 %) had isolated liver and peritoneal metastases and were evaluated in this study. Mean age was 66.9 years, non-mucinous and non-signet-ring cell adenocarcinomas were most prevalent (89.0 %) and tumors were mostly located in the colon (92.1 %). Patients were treated with best supportive care (n = 254, 27,4 %), palliative treatment (n = 618, 66,7 %) or curative treatment (n = 55, 5,9 %). Median OS was 1.5 months, 11.3 months, and 32.6 months, respectively. Multivariable analysis showed that younger age (OR 0.95, p < 0.001) and up to 3 liver metastases (OR 0.13, p < 0.001) are positively associated with receiving curative treatment.</div></div><div><h3>Conclusion</h3><div>This population-based study provides a comprehensive overview of the incidence and treatment of patients with synchronous colorectal liver and peritoneal metastases. It shows that in a highly selected group of patients, curative treatment is associated with better overall survival.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 7","pages":"Article 109999"},"PeriodicalIF":3.5000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ejso","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0748798325004275","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

The aim of this study was to determine the incidence, treatment patterns, survival and factors associated with curative treatment in colorectal cancer patients with combined liver and peritoneal metastases using Dutch population-based data.

Materials and methods

Data from the Netherlands Cancer Registry were used. All patients diagnosed with synchronous isolated peritoneal and liver metastasized colorectal adenocarcinoma between January 1, 2015 and December 31, 2021 were included. Multivariable regression analyses were performed to identify factors associated with receiving curative treatment. Survival rates were calculated for patients undergoing palliative and curative treatment separately.

Results

Of 14627 patients with colorectal adenocarcinoma in the study period, 927 patients (6.3 %) had isolated liver and peritoneal metastases and were evaluated in this study. Mean age was 66.9 years, non-mucinous and non-signet-ring cell adenocarcinomas were most prevalent (89.0 %) and tumors were mostly located in the colon (92.1 %). Patients were treated with best supportive care (n = 254, 27,4 %), palliative treatment (n = 618, 66,7 %) or curative treatment (n = 55, 5,9 %). Median OS was 1.5 months, 11.3 months, and 32.6 months, respectively. Multivariable analysis showed that younger age (OR 0.95, p < 0.001) and up to 3 liver metastases (OR 0.13, p < 0.001) are positively associated with receiving curative treatment.

Conclusion

This population-based study provides a comprehensive overview of the incidence and treatment of patients with synchronous colorectal liver and peritoneal metastases. It shows that in a highly selected group of patients, curative treatment is associated with better overall survival.

查看原文本刊更多论文

结直肠癌合并腹膜和肝脏转移：荷兰全国范围内基于人群的发病率、治疗和生存分析

本研究的目的是利用荷兰人群为基础的数据，确定结直肠癌合并肝和腹膜转移患者的发病率、治疗模式、生存率和与根治性治疗相关的因素。材料和方法使用来自荷兰癌症登记处的数据。纳入2015年1月1日至2021年12月31日期间诊断为同步分离性腹膜和肝转移性结直肠癌的所有患者。进行多变量回归分析以确定与接受治疗相关的因素。分别计算姑息治疗和根治性治疗患者的生存率。结果在研究期间的14627例结直肠癌患者中，927例（6.3%）有分离性肝脏和腹膜转移，并在本研究中进行了评估。平均年龄66.9岁，非黏液和非印戒细胞腺癌发生率最高（89.0%），肿瘤多位于结肠（92.1%）。患者接受最佳支持治疗（n = 254,27,4%），姑息治疗（n = 618,66,7 %）或根治治疗（n = 55,5,9 %）。中位OS分别为1.5个月、11.3个月和32.6个月。多变量分析显示年龄越小(OR 0.95, p <；0.001)和多达3例肝转移(OR 0.13, p <；0.001)与接受治愈性治疗呈正相关。结论：这项以人群为基础的研究提供了同步结肠、肝和腹膜转移患者的发病率和治疗的全面概述。它表明，在一组高度选定的患者中，根治性治疗与更好的总生存率相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ejso 医学-外科

CiteScore

6.40

自引率

2.60%

发文量

1148

审稿时长

41 days

期刊介绍： JSO - European Journal of Surgical Oncology ("the Journal of Cancer Surgery") is the Official Journal of the European Society of Surgical Oncology and BASO ~ the Association for Cancer Surgery. The EJSO aims to advance surgical oncology research and practice through the publication of original research articles, review articles, editorials, debates and correspondence.